CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Palvella Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults, 18 years or older
Meet diagnostic criteria for Gorlin Syndrome
Willing to avoid application of a non-study topical medication to the face (prescription or over the counter) during the study.
Willing to forego treatment of BCCs with anything other than the study medication except when the Investigator believes that delay of treatment of a BCC potentially might compromise the health of the subject. During the trial, the only allowed form of BCC treatment is surgical.
Participant will be encouraged to use their preferred sunscreen with a sun protector factor (SPF) of at least 30 daily
You may not be if
Recently participated in a clinical trial evaluating an investigational product for the treatment of BCCs or Gorlin Syndrome within 3 months prior to to starting study medication. Participant can start the study screening period prior to completing the 3 month washout.
Recently used topical or systemic (oral) treatment that might interfere with the evaluation of the study medication.
Clareo Health | CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
